Although there are several natural and synthetic CPB inhibitors reported [12, 16, 43–48], none of them have been further preclinical evaluated in visceral leishmaniasis models, except for compound K11777, which entered the clinical trials for Chagas disease and was later abandoned due to safety issues [11]. This evidence concerns the gene CPB1 and Chagas disease.